Drug Shortage Report for MYLAN-EMTRICITABINE/TENOFOVIR DISOPROXIL
| Report ID | 82201 |
| Drug Identification Number | 02443902 |
| Brand name | MYLAN-EMTRICITABINE/TENOFOVIR DISOPROXIL |
| Common or Proper name | EMTRICITABINE/TENOFOVIR DISOPROXIL |
| Company Name | MYLAN PHARMACEUTICALS ULC |
| Market Status | MARKETED |
| Active Ingredient(s) | TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE |
| Strength(s) | 300MG 200MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 30 BT |
| ATC code | J05AR |
| ATC description | DIRECT ACTING ANTIVIRALS |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | 2019-06-06 |
| Actual start date | 2019-06-11 |
| Estimated end date | 2019-07-30 |
| Actual end date | 2019-06-25 |
| Shortage status | Resolved |
| Updated date | 2019-06-26 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
| Company contact information | Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.